Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NEOVASC INC (NVCN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/10/2022 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Unaudited Condensed Interim Consolidated Financial Statements for the period ended September 30, 2022",
"Management’s Discussion and Analysis for the period ended September 30, 2022",
"Form 52-109F2 - Certification of Interim Filings - Full Certificate - CEO",
"Form 52-109F2 - Certification of Interim Filings - Full Certificate - CFO",
"Neovasc Announces Third Quarter Financial Results and Provides Corporate Update VANCOUVER and MINNEAPOLIS - - Nov 10, 2022 - Neovasc Inc. today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company received approval to expand the scope of the COSIRA II trial with a registry to include patients suffering from angin..." |
|
| 08/11/2022 |
6-K
| Quarterly results |
| 05/12/2022 |
6-K
| Quarterly results |
| 11/09/2021 |
6-K
| Quarterly results |
| 08/13/2021 |
6-K
| Quarterly results |
| 05/06/2021 |
6-K
| Quarterly results |
| 11/05/2020 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Neovasc Announces Third Quarter Financial Results VANCOUVER and MINNEAPOLIS, November 5, 2020 - Neovasc, Inc. , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2020. Third Quarter Highlights Grew revenue 25% year-over-year in the quarter. Implants increased 50% year-over-year in the quarter including 100% growth in the important DACH countries: Germany, Austria, and Switzerland. Reached the 300 th Reducer patient milestone in Germany, a key Reducer market. Completed a registered direct share offering in August which raised $12.6 million. Continued to strengthen the balance sheet with a partia..." |
|
| 08/06/2020 |
6-K
| Quarterly results |
|
|